Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

March 24, 2023
In the third webinar, we will hear from Jennifer Paquet, RN, BSN, Financial Assistance Patient Care Coordinator Supervisor from Bassett Cancer Institute and Aimee Hoch, MSW, LSW, Oncology Financial Navigator from Grand View Health Cancer Center. We will discuss barriers to radiology prior authorizations and provide insights on how to address them.
Sagar Sardesai, MD MPH Associate Professor, Medical Oncology Medical Director, High Risk Breast Program March 24th, 2023 An Update on Medical Management of High-Risk Women Disclosures ▪ Consultant ▪ Immunomedics ▪ Novartis ▪ Biotheranostic ▪ Gilead ▪ Research Support ▪ AstraZeneca ▪ Immunomedics ▪ Gilead ▪ Senhwa Biosciences ▪ I will be discussing …
First Case of Acquired EGFR C797S Mutation Rendering Resistance to Osimertinib, followed by a near complete response with first generation EGFR TKI in a patient with EGFR mutated NSCLC Jared Reed MD PGY-2 Internal Medicine Resident Marshall University/Edwards Comprehensive Cancer Center Disclosure of Conflicts of Interest • Jared Reed, MD, has no relevant financial …
PowerPoint Presentation Borna Amir-Kabirian, MD PGY2 Internal Medicine Resident Charleston Area Medical Center The Incidence of Venous Thromboembolisms in Pregnancy with Known Cannabis Use DISCLOSURE OF CONFLICTS OF INTEREST • Borna Amir-Kabirian, MD, has no financial relationships to disclose. ACKNOWLEDGEMENTS • Amir Kamran, MD Department of …
Prevalence of UGT1A1 polymorphisms in gastrointestinal cancer: A single-institutional retrospective study Bei Jiang, MD, PhD Hematology and Oncology fellow West Virginia University Disclosure of Conflicts of Interest Bei Jiang, MD, PhD, has no relevant financial relationships to disclose. UGT1A1 polymorphisms conferring increased risk of irinotecan related …
Opportunities to Engage with the NCI Community Oncology Research Program (NCORP) Ann M. Geiger, MPH, PhD Scienti f ic Di rec tor, Cancer Care Del ivery Research, NCORP Heal thcare Del ivery Research Program NCI Div is ion of Cancer Contro l and Population Sc ience 2 Disclosures ▪ None. 3 Topics 1. Context 2. NCI-Supported Trials Networks 3. …
March 24, 2023
The evolving oncology landscape is requiring oncology practices to implement new and innovative approaches for improving care delivery. Experience a collaborative forum that unites leading experts from across the state to explore clinical advances in the pipeline, nuances of new and existing treatments, and the impact of national policies on state-level initiatives. If you are employed by a …
New Molecular Entities • None Changes in Labeled Indications • Opdivo® (nivolumab) and Yervoy® (ipilimumab) – FDA expanded the already approved indication for use of the two IO agents in combination to treat adult patients with unresectable or metastatic melanoma to now include use in treating pediatric patients 12 years of age or older. • Trodelvy® (sacituzumab …
ACCC held a LinkedIn live event on March 13, 2023, with subject matter experts, who shared strategies for tackling lung cancer disparities in the Appalachian Region and beyond.
Annual Meeting Saturday, April 29, 2023 Hutton Hotel Friday, April 28 Welcome Reception Saturday, April 29 7:00 AM Registration/Networking Breakfast 8:00 AM Welcome & Introductions Richard L. Martin, III, MD President, TOPS 8:15 AM Practical Guide to Building Community Research Program David Spigel, MD Tennessee Oncology …
March 22, 2023
In the second webinar, we will hear from Andre D. Harvin, PharmD, MS, Executive Director of Pharmacy for Oncology at Cone Health. We will discuss how your pharmacy team can be a major ally and support in obtaining prior authorizations, help navigate biosimilar changes, and address medical necessity.
New Molecular Entities • None Changes in Labeled Indications • Opdivo® (nivolumab) and Yervoy® (ipilimumab) – FDA expanded the already approved indication for use of the two IO agents in combination to treat adult patients with unresectable or metastatic melanoma to now include use in treating pediatric patients 12 years of age or older. • Trodelvy® (sacituzumab …
If you are looking for legislative action, look no further than your state's legislatures. Most—if not all—states have had issues relating to oncology care and healthcare in general come up during their 2023 sessions.
New Molecular Entities • None Changes in Labeled Indications • Opdivo® (nivolumab) and Yervoy® (ipilimumab) – FDA expanded the already approved indication for use of the two IO agents in combination to treat adult patients with unresectable or metastatic melanoma to now include use in treating pediatric patients 12 years of age or older. • Trodelvy® (sacituzumab …
ACCC joins a broad coalition of patients, advocacy organizations, cancer centers, and healthcare professionals to express support for the Reducing Hereditary Cancer Act. This crucial piece of legislation would address unacceptable care gaps in Medicare beneficiary access to genetic testing for hereditary cancer risk, evidence-based screening, and risk-reducing interventions, when medically necessary …
Reducing Hereditary Cancer Act | Page 1 of 5 March 13, 2023 The Honorable Chuck Schumer Majority Leader U.S. Senate 322 Hart Senate Office Building Washington, DC 20510 The Honorable Mitch McConnell Minority Leader U.S. Senate 317 Russell Senate Office Building Washington, DC 20510 The Honorable Kevin McCarthy Speaker U.S. House of Representatives 2468 Rayburn …
March is Multiple Myeloma Awareness Month. Learn more about the work ACCC is doing to support oncology professionals in treating patients with this disease.
March 20, 2023
In the first webinar, we will hear from Sarah Hudson-DiSalle, PharmD, Rph, Pharmacy Manager, from The James Cancer Hospital, and Jordan Karwedsky, Financial Counselor from Green Bay Oncology. In this webinar, we discuss ACCC Prior Authorization Focus Group findings, payer recommendations, and how to best prepare for the prior authorization "blizzard" for next year.
March 20, 2023
This webinar will explore opportunities to expand multidisciplinary care collaboration and coordination to improve care for patients with non-melanoma skin cancers.